cgp-36742 and Attention-Deficit-Disorder-with-Hyperactivity

cgp-36742 has been researched along with Attention-Deficit-Disorder-with-Hyperactivity* in 1 studies

Reviews

1 review(s) available for cgp-36742 and Attention-Deficit-Disorder-with-Hyperactivity

Article	Year
SGS-742 Novartis. Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:1 SGS-742, a GABA(B) antagonist, is being developed by Saegis, under license from Novartis, for the potential treatment of mild cognitive impairment and Alzheimer's disease (AD). In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients. Topics: Alzheimer Disease; Animals; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Cognition Disorders; GABA Antagonists; Humans; Organophosphorus Compounds	2005

Article

Year

Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:1

SGS-742, a GABA(B) antagonist, is being developed by Saegis, under license from Novartis, for the potential treatment of mild cognitive impairment and Alzheimer's disease (AD). In May 2004, Saegis began enrollment in a phase II trial of SGS-742 in mild-to-moderate AD patients.

Topics: Alzheimer Disease; Animals; Attention Deficit Disorder with Hyperactivity; Clinical Trials as Topic; Cognition Disorders; GABA Antagonists; Humans; Organophosphorus Compounds

2005